glp 1 for cardiovascular disease The Effects of GLP-1 on Health Can GLP-1 agonists treat cardiovascular

Firstly, the extent to which GLP-1R signaling regulates immune cell biology: are these signaling pathways primary mediators or co-participants in the immune response

The PGD is the final authority on eligibility

GIP also exhibits protective effects on the survival of pancreatic beta cells [63]

GLP-1 medications also decrease pancreatic enzyme secretion reducing enzymes like trypsin and lipase by over 40% further impairing fat digestion

These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk

88,89,90,91 A notable study using a porcine model of MI revealed that treatment with adeno-associated virus serotype 6 encoding miR-199a (AAV6-miR-199a) significantly improved overall and regional contractility, increased the myocardial mass, and reduced the scar size